PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2023: Trial registered, NCT05766371
  2. 15 Dec 2023: Trial started, NCT05766371

The trials

NCT05766371: Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

State
Under way
Phase
Phase 2
People
48 planned
Started
15 Dec 2023
Primary completion
31 May 2027
Arms
Pembrolizumab, 177Lu-PSMA-617
Results
None posted
  1. 13 Mar 2023: Trial registered
  2. 15 Dec 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.